CN107033267B - 一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 - Google Patents
一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 Download PDFInfo
- Publication number
- CN107033267B CN107033267B CN201710154947.1A CN201710154947A CN107033267B CN 107033267 B CN107033267 B CN 107033267B CN 201710154947 A CN201710154947 A CN 201710154947A CN 107033267 B CN107033267 B CN 107033267B
- Authority
- CN
- China
- Prior art keywords
- water
- soluble polymers
- compound
- product
- qdi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229920003169 water-soluble polymer Polymers 0.000 title abstract description 33
- 150000001875 compounds Chemical class 0.000 title abstract description 31
- 239000000047 product Substances 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- -1 aminophenylene Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 239000013067 intermediate product Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 239000003999 initiator Substances 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 101710141544 Allatotropin-related peptide Proteins 0.000 claims description 3
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 claims description 3
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 230000005311 nuclear magnetism Effects 0.000 claims description 2
- 229940078552 o-xylene Drugs 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- YOCIJWAHRAJQFT-UHFFFAOYSA-N 2-bromo-2-methylpropanoyl bromide Chemical compound CC(C)(Br)C(Br)=O YOCIJWAHRAJQFT-UHFFFAOYSA-N 0.000 claims 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 41
- 238000003384 imaging method Methods 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000005855 radiation Effects 0.000 abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 230000003685 thermal hair damage Effects 0.000 abstract description 3
- 238000000015 thermotherapy Methods 0.000 abstract description 3
- 238000007385 chemical modification Methods 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 230000035515 penetration Effects 0.000 abstract description 2
- 125000005462 imide group Chemical group 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000012221 photothermal agent Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000007626 photothermal therapy Methods 0.000 description 6
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical class COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ICNCZFQYZKPYMS-UHFFFAOYSA-N 2-methylpropanoyl bromide Chemical compound CC(C)C(Br)=O ICNCZFQYZKPYMS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101100128278 Mus musculus Lins1 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012761 high-performance material Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000007648 laser printing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000002918 oxazolines Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/12—Hydrolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
- C08G2650/04—End-capping
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用。本发明通过在莱啉基化合物的酰亚胺位和“海湾”位的化学修饰,引入极性多支化或线型聚合物,使得疏水苯环骨架的水溶性大大提高,得到一系列具有水溶性、光热功能的基于莱啉基化合物的水溶性聚合物。基于莱啉基化合物吸收光能高效地转化为热能的性质,成功实现了目标产物在小鼠肿瘤的光声成像和光热试剂应用。基于莱啉基化合物的水溶性聚合物具有高生物相容性并且对小鼠脏器及血液的低毒性同时,进入肿瘤组织深处,在定向激光的辐射下,能高效地使肿瘤局部升温,达到精确高效地热疗目的,并且对其它正常组织没有明显的热伤害。
Description
技术领域
本发明属于光热试剂技术领域,特别涉及一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用。本发明是通过在莱啉基化合物的酰亚胺位和“海湾位”的化学修饰得到可用作光热试剂的基于莱啉基化合物的水溶性聚合物。
背景技术
肿瘤已经成为危害人类健康最主要的疾病之一。现阶段癌症的治疗手段主要集中在外科手术、化疗以及放疗:外科手术是快捷的治疗手段,但是由于肿瘤细胞活性没有抑制以及病灶处的物理摘除不彻底,往往伴随着高复发,无法治愈的隐患;化疗和放疗在一定程度上可以有效地抑制癌细胞的活性及复发,通常也伴随着人体正常组织的损伤以及人体免疫机能的下降。利用近红外光的生物组织穿透限制小的特点,近红外激光诱导热疗的肿瘤治疗方法正在兴起。单纯的激光诱导热疗的方式,并不能达到有效的治疗,反而引起肿瘤的爆发式的复发。光热试剂在均匀的分散到组织深处后,接受定向激光的辐射,不仅可以使光能高效地转化为热能,而且能将热能带入深层肿瘤组织,达到治疗的目的。但是无论是已经商业化的试剂,还是已经研究报道过的光热试剂,比如:ICG衍生物,卟啉及其衍生物等,都不能稳定的维持高效的光热转化过程。因此,发明一种稳定的高转化效率的光热试剂,从而达到光诊疗一体的作用,对于生物学、医学研究具有重要的学术及临床转化意义。
由于本身稳定的化学结构,莱啉类化合物具有稳定高效地荧光发射,并且作为优异的能量转化材料在光电、激光打印以及生物检测染色等领域表现了很高的光、热以及化学稳定性。但是由于莱啉类未修饰时,具有强烈的疏水性,所以如果将此高性能的材料引入到生物领域用于光热治疗,第一个亟待解决的问题就是水溶性及生物相容性。
随着光热治疗在临床的逐渐兴起,克服不稳定性,低效的新型光热试剂的设计研发是急需解决的问题。延长共轭度的莱啉类化合物继承了莱啉染料家族的高稳定性,并且可以随着共轭度增加,光热转化效率随之增加的性质。开发一系列基于莱啉基化合物,具有高稳定性和高光热转化效率的的光热试剂,用于癌症及其他疾病的光声成像和光热治疗,具有良好的临床前景。
发明内容
本发明提供了一系列基于莱啉基化合物的水溶性聚合物的制备方法,制备了一系列拓展共轭度后的莱啉染料核修饰水溶性聚合物及其衍生物,并且验证了所得到的莱啉基水溶性聚合物及其衍生物的水溶液能稳定地保持高光热转化效率的特点,在细胞水平以及小鼠水平验证了这一系列聚合物作为光热试剂展开光声成像和光热治疗方法。
本发明所述的一系列基于莱啉基化合物的水溶性聚合物,其由莱啉基化合物和一系列水溶性聚合物及其衍生物反应得到;所述的莱啉基化合物的结构式如(I),
其中,m为重复单元数,取值范围1-4。
X是N、O或者S原子中的任意一种;
R3为支化的反应基团;
R4是未支化的反应基团。
所述的R3含有的官能基团是具有保护性或者活化性的化学基团,所述的官能基团选自苯衍生物基、酰胺、酯键、羟基、硫醇、羧基、卤素、胺类、不饱和烯烃、不饱和炔烃、醚或多肽中的任意至少一种。
所述的R4含有的官能基团是具有保护性或者活化性的化学基团,所述的官能基团选自酰胺、酯键、羟基、硫醇、羧基、卤素、胺类、不饱和烯烃、不饱和炔烃、醚或多肽中的任意至少一种。
优选的,莱啉基化合物和(甲基)丙烯酸酯类及其衍生物、己内酯或丙交酯通过活性可控聚合反应ATRP或开环聚合反应RAFT得到基于莱啉基化合物的水溶性聚合物。
优选的,莱啉基化合物和聚乙二醇或氨基酸类化合物通过酯化反应或酰胺化反应得到含有水溶性侧基的基于莱啉基化合物的水溶性聚合物。
将上述得到的基于莱啉基化合物的水溶性聚合物用作光热试剂。该光热试剂可应用于肿瘤,心血管类等疾病。
本发明将莱啉基化合物用作制备莱啉基水溶性聚合物的聚合反应的引发剂,或者用作制备大分子的反应剂,其修饰水溶性聚合物及其衍生物后(例如丙烯酸或者聚乙二醇衍生物),莱啉基化合物表现出完美的水溶性,克服了苯环骨架强烈的疏水性,得到了一系列具有水溶性聚合物或大分子。延长共轭度后的莱啉基化合物可以高效地吸收近红外光能并且快速转化为热能的性质,并进一步实现了目标产物在细胞(体外)、小鼠(体内)活体水平的光声成像和光热治疗应用。这一系列光热试剂分子具有高生物相容性并且表现了对脏器及血液的低毒性。分子外围水溶性聚合物能将光热分子携带进入肿瘤组织深处,在定向激光的辐射下,能高效地使肿瘤局部升温,不影响正常组织的新陈代谢活动,达到安全高效的热疗目的,并且对其他正常组织没有明显的热伤害。
本发明具有如下的有益效果:
1.本发明设计合成的一系列莱啉基水溶性聚合物及其衍生物具有优异的水溶性,克服了共轭延展度增大带来的水溶性难度。
2.本发明设计合成的一系列莱啉基水溶性聚合物及其衍生物的水溶液具有稳定的光热转化效果,能有效的将吸收的光能转化为热能。
3.本发明设计合成的一系列莱啉基水溶性聚合物及其衍生物的细胞培养基溶液可以在激光辐射条件下快速地产生热效应杀死癌细胞。
4.本发明设计合成的一系列莱啉基水溶性聚合物及其衍生物在小鼠水平可以达到高对比度的光声成像效果。
5.本发明设计合成的一系列莱啉基水溶性聚合物及其衍生物可以快速(12小时内)无痛治愈负瘤小鼠,愈后恢复快且无复发。
附图说明
图1为本发明中基于共轭度延展后的基于莱啉基化合物的水溶性聚合物具有光热效果的主骨架结构。
图2制备一系列共轭度延展的基于莱啉基化合物的水溶性聚合物(实施例1中目标产物TDI-PAA和实施例2中目标产物QDI-PEG)的合成路径。
图3为实施例1中中间产物引发剂的核磁谱图。
图4为本系列新型光热试剂水溶液在可见光-近红外光谱区域的吸收表征。
图5为实施例1中目标产物TDI-PAA不同浓度的水溶液在660nm激光照射下的升温曲线。
图6为实施例1中目标产物TDI-PAA不同浓度的细胞培养基溶液,在660nm激光照射下对癌细胞(4T1和MCF-7)的杀伤效果图。
图7为实施例1中目标产物TDI-PAA不同浓度的水溶液的光声信号,符合线性规律。
图8为实施例1中目标产物TDI-PAA在小鼠肿瘤处的光声成像效果图,随着注射后时间的推移,药物在肿瘤处富集呈现上升再下降趋势,并通过光声信号得以检测。
图9为实施例1中目标产物TDI-PAA进行光热治疗后小鼠肿瘤的变化趋势,可以看出治疗组的肿瘤呈现快速消退,且无复发的变化规律。(对照组条件是PBS,只有药物TNMs,只有激光照射)。
图10为实施例2中中间产物QDI-4OH的质谱谱图。
图11为实施例2中最终产物QDI-PEG的核磁谱图。
图12为实施例2中最终产物QDI-PEG的质谱谱图。
图13为实施例2中目标产物QDI-PEG不同浓度的水溶液在660nm激光照射下的升温曲线。
图14为实施例2中目标产物QDI-PEG不同浓度的细胞培养基溶液,在660nm激光照射下对癌细胞(4T1、MCF-7和HeLa细胞)的杀伤效果图。
图15为实施例2中目标产物QDI-PEG不同浓度的水溶液的光声信号,符合线性规律。
图16为实施例2中目标产物QDI-PEG在小鼠肿瘤处的光声成像效果图,随着注射后时间的推移,药物在肿瘤处富集呈现上升再下降趋势,并通过光声信号得以检测。
图17为实施例2中目标产物QDI-PEG进行光热治疗后小鼠肿瘤的变化趋势,可以看出治疗组的肿瘤呈现快速消退,且无复发的变化规律。(对照组条件是PBS,只有药物QDI-PEG,只有激光照射)。
图18是本发明提供的莱啉基化合物的结构式及用途示例。
具体实施方式
下面将通过实施例并且结合附图对本发明进行进一步详细的描述,但实施例并不用于限制本发明的保护范围。
实施例1
1.将2-溴异丁酰溴(1.5g,7.92mmol)和氨基苯撑(1.0g,2.41mmol)加入0℃反应瓶中,50mL四氢呋喃作为溶剂,7mL三乙胺为缚酸剂,逐渐恢复室温,搅拌反应4-10h;反应结束后,除去溶剂,柱状层析法(二氯甲烷)分离产物得到中间产物标记为CP-NHCOC(CH3)2Br:
1H-NMR谱:(250MHz,CD2Cl2,303K):δ(ppm)=8.38(s,2H,NH),7.43-7.40(d,2H,aromatic H),7.26-7.24(m,10H,aromatic H),6.96-6.92(d,2H,aromatic H),2.01(s,6H;CH3);
13C-NMR谱(75MHz,CD2Cl2,303K):δ(ppm)=200.4,170.6,154.5,138.8,131.8,131.1,130.9,128.8,128.2,126.3,119.7,63.3,32.9.
FD-Mass spectra(8kV):m/z[%]:713(100%)Calcd.for C37H32Br2N2O3(712.49).
2.将步骤1)的产物NHCOC(CH3)2Br(271mg,0.38mmol)和TDI-4Al(50mg,0.038mmol)同时加入微波反应管,溶剂邻二甲苯5mL,反应温度设置为150-200℃,反应结束后用柱状层析法(二氯甲烷)分离产物得到TDI引发剂标记为TDI-initiator:
MS(MALDI-TOF):m/z(%)=4038([M+H]+);(calcd for:4037.41).
1H-NMR(300MHz,CD2Cl2,300K):δppm;9.42(s,4H),8.22-8.18(s,NH,12H),7.55-6.85(m,142H),2.68(m,4H,CH),1.97(s,24H,CH3),1.96(s,24H,CH3),1.13(d,J=6.6Hz,24H,CH3);
13C-NMR(75MHz,CD2Cl2):δppm;170.1,163.5,154.8,154.6,146.5,142.0,141.5,140.3,140.2,139.9,139.3,138.5,137.2,136.8,135.8,131.5,129.8,129.2,126.5,123.4,122.5,119.3,63.1,31.9,29.5,24.2.
3.用步骤2)的产物作为ATRP引发剂,引发丙烯酸叔丁酯单体,(CuBr和DTB-bipy作为催化剂),氮气保护环境,反应温度85℃,通过核磁监控聚合度,得到最终中间产物TDI-P(t-BA),在三氟乙酸条件下得到最终产物树枝状大分子TDI-PAA:
实施例2
1.将QDI-6Br(60mg,0.042mmol)与对乙羟基苯酚(30mg,0.22mmol)加入到含有K2CO3和NMP溶剂的反应瓶中115℃反应48h,反应结束,除去NMP,在正己烷中沉淀后,柱状层析法(二氯甲烷)分离产物得到中间产物标记为QDI-4OH;
2.将步骤1)产物QDI-4OH(50mg,0.03mmol)和分子量2000的PEG-COOH(240mg)混合在二氯甲烷中,在HOBt和DIC体系中常温反应60h以上;冰乙醚中沉淀得到最终产物QDI-PEG;
应用实施例1
取实施例1中所合成的TDI-PAA溶于细胞培养基中,配置成浓度为不同浓度的溶液,和癌细胞共培育5小时,随后用既定功率的激光(1W/cm2)辐射5min,随后用CCK-8方法检测这个过程中癌细胞的存活率,结果如图6所示。
应用实施例2
小鼠体内光声信号测试实验:用PBS水溶液配置实施例1中所合成的TDI-PAA的溶液(0.5mM),然后通过小鼠尾静脉注射,进入小鼠血液循环系统。通过光声仪器(MSOT系统)检测光声信号以及处理为光声照片,结果如图8所示。
应用实施例3
小鼠水平上光热治疗肿瘤实验:用PBS水溶液配置实施例1中所合成的TDI-PAA的溶液(15g/kg),然后通过小鼠尾静脉注射,光热试剂富集在肿瘤组织内部后,通过激光定向的照射,造成肿瘤部位的高温以及接下来的消散。并对接下来肿瘤的体积进行了检测。
应用实施例4
取实施例2中所合成的QDI-PEG溶于细胞培养基中,配置成浓度为不同浓度的溶液,和癌细胞共培育5小时,随后用既定功率的激光(1W/cm2)辐射5min,随后用CCK-8方法检测这个过程中癌细胞的存活率,结果如图14所示。
应用实施例5
小鼠体内光声信号测试实验:用PBS水溶液配置实施例2中所合成的QDI-PEG的溶液(0.5mM),然后通过小鼠尾静脉注射,进入小鼠血液循环系统。通过光声仪器(MSOT系统)检测光声信号以及处理为光声照片,结果如图16所示。
应用实施例6
小鼠水平上光热治疗肿瘤实验:用PBS水溶液配置实施例2中所合成的TDI-PAA的溶液(10g/kg),然后通过小鼠尾静脉注射,光热试剂富集在肿瘤组织内部后,通过激光定向的照射,造成肿瘤部位的高温以及接下来的消散。并对接下来肿瘤的体积进行了检测,结果如图17所示。
综上所述,本发明公开了一系列基于莱啉基化合物的水溶性聚合物及其衍生物制备及其在肿瘤光声成像和光热治疗的医学应用。本发明在莱啉基化合物的外围,通过引入极性多支化或线型聚合物,使得疏水苯环骨架的水溶性大大提高,从而获得一系列具有水溶性、功能性的荧光大分子。基于莱啉基化合物吸收光能高效地转化为热能的性质,实现了目标产物在小鼠活体水平的光声成像和光热治疗应用。一系列莱啉基光热试剂具有高生物相容性并且表现了对脏器及血液的低毒性。分子外围水溶性聚合物能将光热分子携带进入肿瘤组织深处,在定向激光的辐射下,能高效地使肿瘤局部升温,达到高效地热疗目的,并且对其他正常组织没有明显的热伤害。结合前期的研究,这系列光热试剂有希望实现临床转化,达到肿瘤以及其他疾病(如心血管类,皮肤类,肠胃类疾病)领域的应用。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (2)
1.一种光热试剂的制备方法,其特征在于,所述方法的具体步骤为:
1) 将2-溴异丁酰溴7.92 mmol和氨基苯撑2.41 mmol加入0℃反应瓶中,50 mL四氢呋喃作为溶剂,7 mL三乙胺为缚酸剂,逐渐恢复室温,搅拌反应4-10 h;反应结束后,除去溶剂,柱状层析法用溶剂二氯甲烷分离产物得到中间产物NHCOC(CH3)2Br;
2)将步骤1)的产物NHCOC(CH3)2Br0.38mmol和TDI-4Al 0.038mmol同时加入微波反应管,溶剂邻二甲苯5 mL,反应温度设置为150-200℃,反应结束后柱状层析法用溶剂二氯甲烷分离产物得到TDI引发剂标记为TDI-initiator;
3)用步骤2)的产物作为ATRP引发剂,引发丙烯酸叔丁酯单体聚合,CuBr和DTB-bipy作为催化剂,氮气保护环境,反应温度85℃,通过核磁监控聚合度,得到最终中间产物TDI-P(t-BA),在三氟乙酸条件下得到最终产物树枝状大分子TDI-PAA;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710154947.1A CN107033267B (zh) | 2017-03-15 | 2017-03-15 | 一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710154947.1A CN107033267B (zh) | 2017-03-15 | 2017-03-15 | 一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107033267A CN107033267A (zh) | 2017-08-11 |
CN107033267B true CN107033267B (zh) | 2020-04-28 |
Family
ID=59534102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710154947.1A Active CN107033267B (zh) | 2017-03-15 | 2017-03-15 | 一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107033267B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110698665A (zh) * | 2019-08-07 | 2020-01-17 | 浙江海洋大学 | 一种莱啉系基近红外材料的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009056344A1 (en) * | 2007-11-02 | 2009-05-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Core-shell macromolecules for specific cell nucleus or/and cell matrix staining |
CN103204999A (zh) * | 2013-03-22 | 2013-07-17 | 北京化工大学 | 水溶性荧光树枝状大分子的合成方法及其应用 |
CN103539951A (zh) * | 2013-09-29 | 2014-01-29 | 北京化工大学 | 一种水溶性超支化荧光聚合物及其制备方法与应用 |
CN103613692A (zh) * | 2013-11-08 | 2014-03-05 | 北京化工大学 | 一种单分子荧光聚合物胶束及其作为pH探针的应用 |
-
2017
- 2017-03-15 CN CN201710154947.1A patent/CN107033267B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009056344A1 (en) * | 2007-11-02 | 2009-05-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Core-shell macromolecules for specific cell nucleus or/and cell matrix staining |
CN103204999A (zh) * | 2013-03-22 | 2013-07-17 | 北京化工大学 | 水溶性荧光树枝状大分子的合成方法及其应用 |
CN103539951A (zh) * | 2013-09-29 | 2014-01-29 | 北京化工大学 | 一种水溶性超支化荧光聚合物及其制备方法与应用 |
CN103613692A (zh) * | 2013-11-08 | 2014-03-05 | 北京化工大学 | 一种单分子荧光聚合物胶束及其作为pH探针的应用 |
Non-Patent Citations (1)
Title |
---|
"Thermally Polymerized Rylene Nanoparticles";Trisha L. Andrew,etal.;《Macromolecules》;20111231(第44期);第2276-2281页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107033267A (zh) | 2017-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | A near infrared-modulated thermosensitive hydrogel for stabilization of indocyanine green and combinatorial anticancer phototherapy | |
Xu et al. | Synthesis and thermal degradation property study of N-vinylpyrrolidone and acrylamide copolymer | |
CN106008525B (zh) | 一种小分子有机纳米肿瘤光热治疗试剂及其制备方法 | |
Sun et al. | Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers | |
CN110898222B (zh) | 一种基于a-d-a型有机分子/双亲性高分子复合纳米粒子的制备方法及应用 | |
CN112451680B (zh) | 一种具有协同诱导光动力治疗和铁死亡的ros敏感性纳米试剂及其制备方法 | |
CN101687040A (zh) | 整合光活性的小分子及其用途 | |
EP2001857A2 (en) | Photoactive compounds and compositions and uses thereof | |
AU2016259188B2 (en) | Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof | |
CN113773667A (zh) | 有机小分子近红外二区荧光染料及其制备方法和应用 | |
CN107033267B (zh) | 一系列基于莱啉基化合物的水溶性聚合物的制备及其作为光热试剂在生物医学的应用 | |
Wang et al. | A novel approach to synthesize polymers for potential photodynamic therapy: from benzenedinitrile to phthalocyanine | |
CN110859823A (zh) | 光热敏感型羧甲基壳聚糖纳米载药微球及其制备方法 | |
Zhang et al. | A single-wavelength NIR-triggered polymer for in situ generation of peroxynitrite (ONOO−) to enhance phototherapeutic efficacy | |
Umar et al. | Synthesis and relaxivity measurement of porphyrin-based Magnetic Resonance Imaging (MRI) contrast agents | |
Tian et al. | Porphyrin-based porous organic polymer coated ZIF-8 nanoparticles as tumor targeted photosensitizer for combination cancer photodynamic/photothermal therapy | |
Fan et al. | Enhanced drug retention by anthracene crosslinked nanocomposites for bimodal imaging-guided phototherapy | |
CN111686250A (zh) | 一种线粒体靶向的光热治疗剂及其制备和应用 | |
CN113683602B (zh) | 一种用于缺氧肿瘤多模态治疗的七甲川花菁小分子和制备方法及应用 | |
KR101493889B1 (ko) | 광역학 진단 또는 치료용 광감작제 및 그 제조방법 | |
CN110003086A (zh) | 一种两亲性小分子ir820-1mt及其制剂以及其制备方法和应用 | |
CN105833293B (zh) | 一种新型纳米诊断治疗胶束及其应用 | |
CN114931649A (zh) | 一种响应释放一氧化碳的纳米颗粒及其制备方法和应用 | |
Yang et al. | Photothermally triggered disassembly of a visible dual fluorescent poly (ethylene glycol)/α-cyclodextrin hydrogel | |
CN108864116A (zh) | 一种新型二氢卟吩e6衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |